Search by Drug Name or NDC
NDC 28595-0224-60 URIMAR-T CAPS .12; 120; 10.8; 36.2; 40.8 mg/1; mg/1; mg/1; mg/1; mg/1 Details
URIMAR-T CAPS .12; 120; 10.8; 36.2; 40.8 mg/1; mg/1; mg/1; mg/1; mg/1
URIMAR-T CAPS is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Allegis Pharmaceuticals, LLC. The primary component is HYOSCYAMINE SULFATE; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE.
Product Information
| NDC | 28595-0224 |
|---|---|
| Product ID | 28595-224_ffd1abb5-8b32-424e-e053-6394a90aed4c |
| Associated GPIs | |
| GCN Sequence Number | 085037 |
| GCN Sequence Number Description | meth/meblue/sod phos/psal/hyos CAPSULE 120-10.8MG ORAL |
| HIC3 | W2G |
| HIC3 Description | ANTIBIOTIC, ANTIBACTERIAL, MISC. |
| GCN | 54476 |
| HICL Sequence Number | 034934 |
| HICL Sequence Number Description | METHENAMINE/METHYLENE BLUE/SOD PHOS/P.SALICYLATE/HYOSCYAMINE |
| Brand/Generic | Generic |
| Proprietary Name | URIMAR-T CAPS |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | .12; 120; 10.8; 36.2; 40.8 |
| Active Ingredient Units | mg/1; mg/1; mg/1; mg/1; mg/1 |
| Substance Name | HYOSCYAMINE SULFATE; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE |
| Labeler Name | Allegis Pharmaceuticals, LLC |
| Pharmaceutical Class | Oxidation-Reduction Activity [MoA], Oxidation-Reduction Agent [EPC] |
| DEA Schedule | n/a |
| Marketing Category | UNAPPROVED DRUG OTHER |
| Application Number | n/a |
| Listing Certified Through | 2024-12-31 |
Package
NDC 28595-0224-60 (28595022460)
| NDC Package Code | 28595-224-60 |
|---|---|
| Billing NDC | 28595022460 |
| Package | 60 CAPSULE in 1 BOTTLE (28595-224-60) |
| Marketing Start Date | 2023-06-28 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |